KZIA News

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering

Kazia Therapeutics Limited Announces Proposed Public Offering

Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer

Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer

The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

Kazia Therapeutics Appoints James Levine as Chief Financial Officer